Author’s response to reviews

Title: Endothelial Cell-Specific Molecule-1 as an Invasiveness Marker for Pituitary Null Cell Adenoma

Authors:
Shousen Wang (wshsen1965@126.com)
Zhifeng Wu (turanwangle@sina.com)
Liangfeng Wei (wlf74@163.com)
Jianhe Zhang (leo200303034@126.com)

Version: 2 Date: 18 Jul 2019

Author’s response to reviews:

July 17, 2019

Dr. Zuleyha Karaca
BMC Endocrine Disorders
https://bmcendocrdisord.biomedcentral.com/

Re: Ms. Ref. No.: BEND-D-19-00130R1

Dear Dr. Zuleyha Karaca,

We thank you for the opportunity to revise our manuscript, entitled “Endothelial Cell-Specific Molecule-1 as an Invasiveness Marker for Pituitary Null Cell Adenoma”.

Detailed point-by-point replies to the reviewers’ comments in addition to our revised manuscript have been resubmitted. All changes have been made in the revised manuscript. We hope our revised manuscript could be acceptable for publication in BMC Endocrine Disorders. We thank you once more for your time and consideration.

Sincerely,

Shousen Wang

Reviewer reports:
Takatoshi Anno, MD, PhD (Reviewer 1): The revised manuscript has been appropriately amended. So, I have no further comments to this manuscript.

Assistant Editor Comments:

1. Conclusion

Please include a separate Conclusions section under a "Conclusions" heading.

Response: We’ve included a separate Conclusions section under a "Conclusions" heading.

2. Consent to participate

In your “ethical approval and consent to participate” section, please confirm whether informed consent obtained was written or verbal.

Response: We’ve revised the sentence accordingly.

3. Availability of data and materials

The Availability of data and materials section refers to the raw data used in your study and presenting tables and figures is not sufficient to state that all data is contained within the manuscript and additional files. Please only use this statement if you have indeed provided all raw data on which your study is based.

Otherwise, please clearly state who should be contacted if someone wants to request the data. For example, you may instead state the raw data available upon reasonable request from the corresponding authors in the “Availability of data and materials” section of the declarations.

Response: We’ve revised the sentence accordingly.

4. Funding

In the Funding section, please also describe the role of the funding body in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Response: We’ve revised the sentence accordingly.

5. Authors' Contributions
Please represent authors' names using their full initials, not their full name, in the Authors’ Contributions section. If there are any duplicated initials, please differentiate them to make it clear that the initials refer to separate authors.

Response: We’ve revised the full initials accordingly.

6. Figures

Please bear in mind that multi-panel figures (those with parts a, b, c, d etc.) should be submitted as a single composite file that contains all parts of the figure. Please ensure to submit Fig 1A, 1B, 1C and 1D as a single file that contains all four parts of the figure.

Response: We’ve revised the figure 1.

7. Formatting

-- In your Abstract please rename your "Objective" heading to "Background".

-- In your main manuscript, please rename your "Introduction" heading to "Background".

-- In your main manuscript, please rename your "Patients and Methods" heading to "Methods".

Response: We’ve revised the formatting accordingly.

8. Clean manuscript

At this stage, please upload your manuscript as a single, final, clean version that does not contain any tracked changes, comments, highlights, strikethroughs or text in different colours. All relevant tables/figures/additional files should also be clean versions. Figures (and additional files) should remain uploaded as separate files. Please ensure that all figures, tables and additional/supplementary files are cited within the text.